Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp - 15/10/15
Abstract |
Background |
Vismodegib has been approved for treatment of locally advanced or metastatic basal cell carcinoma (BCC). Its use for postirradiation multiple BCCs has not yet been reported.
Objective |
We sought to investigate the effectiveness and safety of vismodegib for the treatment of recurrent radiation-induced multiple BCCs.
Methods |
Patients with recurrent multiple BCCs treated with vismodegib and a history of exposure to radiation treatment were followed up prospectively at a tertiary dermato-oncology clinic during a 19-month period.
Results |
Eight patients met the study criteria. Mean duration of vismodegib treatment was 29 weeks (range 2-52), and of follow-up, 34 weeks (range 8-64). Drug tolerability was acceptable in 7 patients, of whom 4 showed a partial response and 3 had stable disease. In 1 patient, vismodegib was discontinued soon after its initiation because of a severe drug-induced eruption.
Limitations |
Small sample size and short follow-up time are limitations.
Conclusion |
Vismodegib holds promise for the treatment of the subpopulation of patients with radiation-induced multiple BCCs in whom therapeutic options have so far been limited.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, Hedgehog, radiotherapy, skin cancer, tinea capitis, vismodegib
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 73 - N° 5
P. 799-801 - novembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?